Search

Your search keyword '"Azambuja, Evandro"' showing total 923 results
Start Over Author "Azambuja, Evandro" Search Limiters Full Text
923 results on '"Azambuja, Evandro"'

1. Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)

Author

Nader-Marta, Guilherme, Singer, Christian, Hlauschek, Dominik, DeMichele, Angela, Tarantino, Paolo, de Azambuja, Evandro, Pfeiler, Georg, Martin, Miguel, Balko, Justin M., Nowecki, Zbigniew, Balic, Marija, Brufsky, Adam M., Chan, Arlene, Morris, Patrick G., Haddad, Tufia, Loibl, Sibylle, Liu, Yuan, Soelkner, Lidija, Fesl, Christian, Mayer, Erica L., and Gnant, Michael

Published
2024
Full Text
View/download PDF

3. Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study

Author

Arecco, Luca, Latocca, Maria Maddalena, Blondeaux, Eva, Riccardi, Ferdinando, Mocerino, Carmela, Guarneri, Valentina, Mioranza, Eleonora, Bisagni, Giancarlo, Gasparini, Elisa, Puglisi, Fabio, Membrino, Alexandro, Ferro, Antonella, Adamo, Vincenzo, Giovanardi, Filippo, Tamberi, Stefano, Donati, Sara, Landucci, Elisabetta, Biganzoli, Laura, Piccinini, Sara, Pastorino, Simona, de Azambuja, Evandro, Poggio, Francesca, Lambertini, Matteo, and Del Mastro, Lucia

Published
2024
Full Text
View/download PDF

5. Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Author

Buisseret, Laurence, Loirat, Delphine, Aftimos, Philippe, Maurer, Christian, Punie, Kevin, Debien, Véronique, Kristanto, Paulus, Eiger, Daniel, Goncalves, Anthony, Ghiringhelli, François, Taylor, Donatienne, Clatot, Florent, Van den Mooter, Tom, Ferrero, Jean-Marc, Bonnefoi, Hervé, Canon, Jean-Luc, Duhoux, Francois P., Mansi, Laura, Poncin, Renaud, Barthélémy, Philippe, Isambert, Nicolas, Denis, Zoë, Catteau, Xavier, Salgado, Roberto, Agostinetto, Elisa, de Azambuja, Evandro, Rothé, Françoise, Craciun, Ligia, Venet, David, Romano, Emanuela, Stagg, John, Paesmans, Marianne, Larsimont, Denis, Sotiriou, Christos, Ignatiadis, Michail, and Piccart-Gebhart, Martine

Published
2023
Full Text
View/download PDF

6. Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Author

Buisseret, Laurence, Loirat, Delphine, Aftimos, Philippe, Maurer, Christian, Punie, Kevin, Debien, Véronique, Kristanto, Paulus, Eiger, Daniel, Goncalves, Anthony, Ghiringhelli, François, Taylor, Donatienne, Clatot, Florent, Van den Mooter, Tom, Ferrero, Jean-Marc, Bonnefoi, Hervé, Canon, Jean-Luc, Duhoux, Francois P., Mansi, Laura, Poncin, Renaud, Barthélémy, Philippe, Isambert, Nicolas, Denis, Zoë, Catteau, Xavier, Salgado, Roberto, Agostinetto, Elisa, de Azambuja, Evandro, Rothé, Françoise, Craciun, Ligia, Venet, David, Romano, Emanuela, Stagg, John, Paesmans, Marianne, Larsimont, Denis, Sotiriou, Christos, Ignatiadis, Michail, and Piccart-Gebhart, Martine

Published
2023
Full Text
View/download PDF

8. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Author

Tutt, Andrew NJ, Garber, Judy E, Kaufman, Bella, Viale, Giuseppe, Fumagalli, Debora, Rastogi, Priya, Gelber, Richard D, de Azambuja, Evandro, Fielding, Anitra, Balmaña, Judith, Domchek, Susan M, Gelmon, Karen A, Hollingsworth, Simon J, Korde, Larissa A, Linderholm, Barbro, Bandos, Hanna, Senkus, Elżbieta, Suga, Jennifer M, Shao, Zhimin, Pippas, Andrew W, Nowecki, Zbigniew, Huzarski, Tomasz, Ganz, Patricia A, Lucas, Peter C, Baker, Nigel, Loibl, Sibylle, McConnell, Robin, Piccart, Martine, Schmutzler, Rita, Steger, Guenther G, Costantino, Joseph P, Arahmani, Amal, Wolmark, Norman, McFadden, Eleanor, Karantza, Vassiliki, Lakhani, Sunil R, Yothers, Greg, Campbell, Christine, and Geyer, Charles E

Subjects
Digestive Diseases, Breast Cancer, Cancer, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adult, Antineoplastic Agents, Breast Neoplasms, Chemotherapy, Adjuvant, Disease-Free Survival, Double-Blind Method, Female, Genes, BRCA1, Genes, BRCA2, Germ-Line Mutation, Humans, Mastectomy, Middle Aged, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerase Inhibitors, Receptor, ErbB-2, OlympiA Clinical Trial Steering Committee and Investigators, Receptor, erbB-2, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundPoly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer.MethodsWe conducted a phase 3, double-blind, randomized trial involving patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors who had received local treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomly assigned (in a 1:1 ratio) to 1 year of oral olaparib or placebo. The primary end point was invasive disease-free survival.ResultsA total of 1836 patients underwent randomization. At a prespecified event-driven interim analysis with a median follow-up of 2.5 years, the 3-year invasive disease-free survival was 85.9% in the olaparib group and 77.1% in the placebo group (difference, 8.8 percentage points; 95% confidence interval [CI], 4.5 to 13.0; hazard ratio for invasive disease or death, 0.58; 99.5% CI, 0.41 to 0.82; P

Published
2021

9. Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

Author

Debien, Veronique, Marta, Guilherme Nader, Agostinetto, Elisa, Sirico, Marianna, Jacobs, Flavia, Molinelli, Chiara, Moreau, Michel, Paesmans, Marianne, De Giorgi, Ugo, Santoro, Armando, Taylor, Donatienne, Duhoux, François P., Botticelli, Andrea, Barchiesi, Giacomo, Speranza, Iolanda, Lambertini, Matteo, Wildiers, Hans, Azambuja, Evandro de, and Piccart, Martine

Published
2023
Full Text
View/download PDF

10. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

Author

Lambertini, Matteo, Blondeaux, Eva, Bisagni, Giancarlo, Mura, Silvia, De Placido, Sabino, De Laurentiis, Michelino, Fabi, Alessandra, Rimanti, Anita, Michelotti, Andrea, Mansutti, Mauro, Russo, Antonio, Montemurro, Filippo, Frassoldati, Antonio, Durando, Antonio, Gori, Stefania, Turletti, Anna, Tamberi, Stefano, Urracci, Ylenia, Fregatti, Piero, Razeti, Maria Grazia, Caputo, Roberta, De Angelis, Carmine, Sanna, Valeria, Gasparini, Elisa, Agostinetto, Elisa, de Azambuja, Evandro, Poggio, Francesca, Boni, Luca, and Del Mastro, Lucia

Published
2023
Full Text
View/download PDF

11. Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study

Author

Nader-Marta, Guilherme, Debien, Véronique, Eiger, Daniel, Tsourti, Zoi, Caparica, Rafael, Kassapian, Marie, Napoleone, Sylvia, Hultsch, Susanne, Korde, Larissa, Wang, Yingbo, Chumsri, Saranya, Pritchard, Kathleen I., Untch, Michael, Bellet-Ezquerra, Meritxell, Dornelles Rosa, Daniela, Moreno-Aspitia, Alvaro, Piccart, Martine, Dafni, Urania, and de Azambuja, Evandro

Published
2022
Full Text
View/download PDF

12. PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer

Author

Agostinetto, Elisa, Ameye, Lieveke, Martel, Samuel, Aftimos, Philippe, Pondé, Noam, Maurer, Christian, El-Abed, Sarra, Wang, Yingbo, Vicente, Malou, Chumsri, Saranya, Bliss, Judith, Kroep, Judith, Colleoni, Marco, Petrelli, Fausto, Del Mastro, Lucia, Moreno-Aspitia, Alvaro, Piccart, Martine, Paesmans, Marianne, de Azambuja, Evandro, and Lambertini, Matteo

Published
2022
Full Text
View/download PDF

15. Ovarian Suppression: Early Menopause and Late Effects

Author

Molinelli, Chiara, Jacobs, Flavia, Marta, Guilherme Nader, Borea, Roberto, Scavone, Graziana, Ottonello, Silvia, Fregatti, Piero, Villarreal-Garza, Cynthia, Bajpai, Jyoti, Kim, Hee Jeong, Puglisi, Silvia, de Azambuja, Evandro, Lambertini, Matteo Md Phd M., Molinelli, Chiara, Jacobs, Flavia, Marta, Guilherme Nader, Borea, Roberto, Scavone, Graziana, Ottonello, Silvia, Fregatti, Piero, Villarreal-Garza, Cynthia, Bajpai, Jyoti, Kim, Hee Jeong, Puglisi, Silvia, de Azambuja, Evandro, and Lambertini, Matteo Md Phd M.

Abstract

Around 90% of breast tumours are diagnosed in the early stage, with approximately 70% being hormone receptor-positive. The cornerstone of adjuvant therapy for early-stage hormone receptor-positive breast cancer is endocrine therapy, tailored according to disease stage, biological characteristics of the tumour, patient’s comorbidities, preferences and age. In premenopausal patients with hormone receptor-positive breast cancer, ovarian function suppression is a key component of the adjuvant endocrine treatment in combination with an aromatase inhibitor or tamoxifen. Moreover, it can be used during chemotherapy as a standard strategy for ovarian function preservation in all breast cancer subtypes. In the metastatic setting, ovarian function suppression should be used in all premenopausal patients with hormone receptor-positive breast cancer to achieve a post-menopausal status. Despite its efficacy, ovarian function suppression may lead to several side effects that can have a major negative impact on patients’ quality of life if not properly managed (e.g. hot flashes, depression, cognitive impairment, osteoporosis, sexual dysfunction, weight gain). A deep knowledge of the side effects of ovarian function suppression is necessary for clinicians. A correct counselling in this regard and proactive management should be considered a fundamental part of survivorship care to improve treatment adherence and patients’ quality of life., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2024

16. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

Author

Kaidar-Person, Orit, Meattini, Icro, Boersma, Liesbeth L.J., Becherini, Carlotta, Cortes, Javier, Curigliano, Giuseppe, de Azambuja, Evandro, Harbeck, Nadia, Rugo, Hope H.S., Del Mastro, Lucia, Gennari, Alessandra, Isacke, Clare Marie, Vestmø Maraldo, Maja, Marangoni, E., Nader Marta, Gustavo, Mjaaland, Ingvil, Salvestrini, Viola, Španić, Tanja, Visani, Luca, Morandi, Andrea, Lambertini, Matteo Md Phd M., Livi, Lorenzo, Coles, Charlotte Elizabeth, Poortmans, Philipp, Offersen, Birgitte Vrou, Kaidar-Person, Orit, Meattini, Icro, Boersma, Liesbeth L.J., Becherini, Carlotta, Cortes, Javier, Curigliano, Giuseppe, de Azambuja, Evandro, Harbeck, Nadia, Rugo, Hope H.S., Del Mastro, Lucia, Gennari, Alessandra, Isacke, Clare Marie, Vestmø Maraldo, Maja, Marangoni, E., Nader Marta, Gustavo, Mjaaland, Ingvil, Salvestrini, Viola, Španić, Tanja, Visani, Luca, Morandi, Andrea, Lambertini, Matteo Md Phd M., Livi, Lorenzo, Coles, Charlotte Elizabeth, Poortmans, Philipp, and Offersen, Birgitte Vrou

Abstract

The European Society for Radiotherapy and Oncology (ESTRO) has advocated the establishment of guidelines to optimise precision radiotherapy (RT) in conjunction with contemporary therapeutics for cancer care. Quality assurance in RT (QART) plays a pivotal role in influencing treatment outcomes. Clinical trials incorporating QART protocols have demonstrated improved survival rates with minimal associated toxicity. Nonetheless, in routine clinical practice, there can be variability in the indications for RT, dosage, fractionation, and treatment planning, leading to uncertainty. In pivotal trials reporting outcomes of systemic therapy for breast cancer, there is limited information available regarding RT, and the potential interaction between modern systemic therapy and RT remains largely uncharted. This article is grounded in a consensus recommendation endorsed by ESTRO, formulated by international breast cancer experts. The consensus was reached through a modified Delphi process and was presented at an international meeting convened in Florence, Italy, in June 2023. These recommendations are regarded as both optimal and essential standards, with the latter aiming to define the minimum requirements. A template for a case report form (CRF) has been devised, which can be utilised by all clinical breast cancer trials involving RT. Optimal requirements include adherence to predefined RT planning protocols and centralised QART. Essential requirements aim to reduce variations and deviations from the guidelines in RT, even when RT is not the primary focus of the trial. These recommendations underscore the significance of implementing these practices in both clinical trials and daily clinical routines to generate high-quality data., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2024

19. Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial

Author

Lambertini, Matteo, Agbor-Tarh, Dominique, Metzger-Filho, Otto, Ponde, Noam F., Poggio, Francesca, Hilbers, Florentine S., Korde, Larissa A., Chumsri, Saranya, Werner, Olena, Del Mastro, Lucia, Caparica, Rafael, Moebus, Volker, Moreno-Aspitia, Alvaro, Piccart, Martine J., and de Azambuja, Evandro

Published
2020
Full Text
View/download PDF

21. Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis

Author

de Azambuja, Evandro, Brandão, Mariana, Wildiers, Hans, Laenen, Annouschka, Aspeslagh, Sandrine, Fontaine, Christel, Collignon, Joelle, Lybaert, Willem, Verheezen, Jolanda, Rutten, Annemie, Vuylsteke, Peter, Goeminne, Jean-Charles, Demey, Wim, Van Beckhoven, Dominique, Deblonde, Jessika, Rottey, Sylvie, Geukens, Tatjana, Punie, Kevin, Bafort, Kristof, Belkhir, Leïla, Bossuyt, Nathalie, Colombie, Vincent, Daubresse, Christine, Dauby, Nicolas, De Munter, Paul, Delmarcelle, Didier, Delvallee, Mélanie, Demeester, Rémy, Delefortrie, Quentin, Dugernier, Thierry, Holemans, Xavier, Louviaux, Ingrid, Machurot, PierreYves, Minette, Philippe, Mokrane, Saphia, Nachtergal, Catherine, Noirhomme, Séverine, Piérard, Denis, Rossi, Camelia, Schirvel, Carole, Sermijn, Erica, Staelens, Frank, Triest, Filip, Van Goethem, Nina, Van Praet, Jens, Vanhoenacker, Anke, Verstraete, Roeland, Willems, Elise, and Wyndham-Thomas, Chloé

Published
2020
Full Text
View/download PDF

23. European Society of Cardiology Core Curriculum for Cardio‐Oncology

Author

López‐Fernández, Teresa, primary, Farmakis, Dimitrios, additional, Ameri, Pietro, additional, Asteggiano, Riccardo, additional, de Azambuja, Evandro, additional, Aznar, Marianne, additional, Barac, Ana, additional, Bayes‐Genis, Antoni, additional, Bax, Jeroen J., additional, Bergler‐Klein, Jutta, additional, Boriani, Giuseppe, additional, Celutkiene, Jelena, additional, Coats, Andrew, additional, Cohen‐Solal, Alain, additional, Córdoba, Raúl, additional, Cosyns, Bernard, additional, Filippatos, Gerasimos, additional, Fox, Kevin, additional, Gulati, Geeta, additional, Inciardi, Riccardo M., additional, Lee, Geraldine, additional, Mamas, Mamas A., additional, Novo, Giuseppina, additional, Plummer, Chris, additional, Psyrri, Amanda, additional, Rakisheva, Amina, additional, Suter, Thomas, additional, Tini, Giacomo, additional, Tocchetti, Carlo Gabriele, additional, Toutouzas, Konstantinos, additional, Wilhelm, Matthias, additional, Metra, Marco, additional, Lyon, Alexander R., additional, and Rosano, Giuseppe M. C., additional

Published
2023
Full Text
View/download PDF

24. Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months

Author

de las Heras, Begoña, Saini, Kamal S., Boyle, Frances, Ades, Felipe, de Azambuja, Evandro, Bozovic-Spasojevic, Ivana, Romano, Marco, Capelan, Marta, Prasad, Rajeev, Pattu, Pugazhenthi, Massard, Christophe, Portera, Chia, Saini, Monika Lamba, Singh, Brajendra Prasad, Venkitaraman, Ramachandran, McNally, Richard, Leone, Manuela, Grande, Enrique, and Gupta, Sudeep

Published
2020
Full Text
View/download PDF

27. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

Author

Eiger, Daniel, Pondé, Noam F., Agbor-Tarh, Dominique, Moreno-Aspitia, Alvaro, Piccart, Martine, Hilbers, Florentine S., Werner, Olena, Chumsri, Saranya, Dueck, Amylou, Kroep, Judith R., Gomez, Henry, Láng, István, Rodeheffer, Richard J., Ewer, Michael S., Suter, Thomas, and de Azambuja, Evandro

Published
2020
Full Text
View/download PDF

29. European Society of Cardiology Core Curriculum for cardio‐oncology.

Author

López‐Fernández, Teresa, Farmakis, Dimitrios, Ameri, Pietro, Asteggiano, Riccardo, de Azambuja, Evandro, Aznar, Marianne, Barac, Ana, Bayes‐Genis, Antoni, Bax, Jeroen J., Bergler‐Klein, Jutta, Boriani, Giuseppe, Celutkiene, Jelena, Coats, Andrew, Cohen‐Solal, Alain, Córdoba, Raúl, Cosyns, Bernard, Filippatos, Gerasimos, Fox, Kevin, Gulati, Geeta, and Inciardi, Riccardo M.

Subjects
CARDIO-oncology, REQUIRED courses (Education), CARDIOTOXICITY, CARDIOLOGY, DISEASE management
Abstract

Cardio‐oncology is a rapidly growing field of cardiovascular (CV) medicine that has resulted from the continuously increasing clinical demand for specialized CV evaluation, prevention and management of patients suffering or surviving from malignant diseases. Dealing with CV disease in patients with cancer requires special knowledge beyond that included in the general core curriculum for cardiology. Therefore, the European Society of Cardiology (ESC) has developed a special core curriculum for cardio‐oncology, a consensus document that defines the level of experience and knowledge required for cardiologists in this particular field. It is structured into 8 chapters, including (i) principles of cancer biology and therapy; (ii) forms and definitions of cancer therapy‐related cardiovascular toxicity (CTR‐CVT); (iii) risk stratification, prevention and monitoring protocols for CTR‐CVT; (iv) diagnosis and management of CV disease in patients with cancer; (v) long‐term survivorship programmes and cardio‐oncology rehabilitation; (vi) multidisciplinary team management of special populations; (vii) organization of cardio‐oncology services; (viii) research in cardio‐oncology. The core curriculum aims at promoting standardization and harmonization of training and evaluation in cardio‐oncology, while it further provides the ground for an ESC certification programme designed to recognize the competencies of certified specialists. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Supportive care after curative treatment for breast cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement

Author

Ganz, Patricia A, Yip, Cheng Har, Gralow, Julie R, Distelhorst, Sandra R, Albain, Kathy S, Andersen, Barbara L, Bevilacqua, Jose Luiz B, de Azambuja, Evandro, Saghir, Nagi S El, Kaur, Ranjit, McTiernan, Anne, Partridge, Ann H, Rowland, Julia H, Singh-Carlson, Savitri, Vargo, Mary M, Thompson, Beti, and Anderson, Benjamin O

Subjects
Clinical Research, Pain Research, Health Services, Breast Cancer, Cancer, Rehabilitation, Mind and Body, Prevention, 7.3 Management and decision making, Management of diseases and conditions, 7.1 Individual care needs, Quality Education, Antineoplastic Agents, Body Image, Breast Neoplasms, Depression, Developing Countries, Fatigue, Female, Health Personnel, Humans, Life Style, Lymphedema, Menopause, Neoplasm Recurrence, Local, Pain Management, Patient Education as Topic, Postoperative Complications, Resource Allocation, Self Care, Sexual Behavior, Sleep Initiation and Maintenance Disorders, Survivors, Breast cancer, Supportive care, Survivorship, Low- and middle-income countries, Resource allocations, Clinical Sciences, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

Breast cancer survivors may experience long-term treatment complications, must live with the risk of cancer recurrence, and often experience psychosocial complications that require supportive care services. In low- and middle-income settings, supportive care services are frequently limited, and program development for survivorship care and long-term follow-up has not been well addressed. As part of the 5th Breast Health Global Initiative (BHGI) Global Summit, an expert panel identified nine key resources recommended for appropriate survivorship care, and developed resource-stratified recommendations to illustrate how health systems can provide supportive care services for breast cancer survivors after curative treatment, using available resources. Key recommendations include health professional education that focuses on the management of physical and psychosocial long-term treatment complications. Patient education can help survivors transition from a provider-intense cancer treatment program to a post-treatment provider partnership and self-management program, and should include: education on recognizing disease recurrence or metastases; management of treatment-related sequelae, and psychosocial complications; and the importance of maintaining a healthy lifestyle. Increasing community awareness of survivorship issues was also identified as an important part of supportive care programs. Other recommendations include screening and management of psychosocial distress; management of long-term treatment-related complications including lymphedema, fatigue, insomnia, pain, and women's health issues; and monitoring survivors for recurrences or development of second primary malignancies. Where possible, breast cancer survivors should implement healthy lifestyle modifications, including physical activity, and maintain a healthy weight. Health professionals should provide well-documented patient care records that can follow a patient as they transition from active treatment to follow-up care.

Published
2013

38. OncoAlert Round Table Discussions: The Global COVID-19 Experience

Author

Morgan, Gilberto, de Azambuja, Evandro, Punie, Kevin, Ades, Felipe, Heinrich, Kathrin, Personeni, Nicola, Rahme, Ramy, Ferrara, Roberto, Pels, Kevin, Garassino, Marina, von Bergwelt-Baildon, Michael, Lopes, Gilberto, Barlesi, Fabrice, Choueiri, Toni K., Burris, Howard, and Peters, Solange

Published
2021
Full Text
View/download PDF

40. Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis.

Author

Cunha, Mateus Trinconi, Gouveia, Mariana Carvalho, Neto, Felippe Lazar, Testa, Laura, Hoff, Paulo Marcelo, de Azambuja, Evandro, and Bonadio, Renata Colombo

Abstract

Background: Neoadjuvant immunotherapy (nIO) has emerged as a treatment option for stage II–III triple-negative breast cancer (TNBC). While randomised clinical trials (RCTs) demonstrated pathological complete response rate benefit to nIO added to chemotherapy, additional data on long-term outcomes is warranted. We performed this analysis to evaluate long-term efficacy outcomes of nIO in TNBC. Methods: We searched databases for RCTs evaluating nIO in early-stage TNBC. A meta-analysis of extracted individual patient data (EIPD) was performed to evaluate EFS and OS, with data from reported Kaplan–Meier plots. Additionally, we conducted a trial-level meta-analysis using fixed and random effects models. Results: The literature search resulted in four included RCTs with available EFS or OS (KEYNOTE-522, IMpassion031, I-SPY2 and GeparNuevo). EIPD showed that the addition of nIO to chemotherapy provides statistically significant benefits in EFS (HR 0.62, 0.50–0.76; p < 0.001) and OS (HR 0.62, 0.46–0.82, p < 0.001). Number needed to treat to avoid one EFS or OS event in 4 years was 9 and 14, respectively. Trial-level meta-analysis yielded similar results (EFS: HR 0.64, 0.51–0.79; OS: 0.57, 0.37–0.89). Conclusions: Results show that nIO combined with chemotherapy can provide significant EFS and OS benefits, supporting its use as standard treatment for early-stage TNBC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. COVID-19 in cancer patients: Update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases

Author

Martin, Pierre, primary, Tsourti, Zoi, additional, Ribeiro, Joana, additional, Castelo-Branco, Luis, additional, de Azambuja, Evandro, additional, Gennatas, Spyridon, additional, Rogado, Jacobo, additional, Sekacheva, Marina, additional, Šušnjar, Snežana, additional, Viñal, David, additional, Lee, Rebecca, additional, Khallaf, Salah, additional, Dimopoulou, Georgia, additional, Pradervand, Sylvain, additional, Whisenant, Jennifer, additional, Choueiri, Toni K., additional, Arnold, Dirk, additional, Harrington, Kevin, additional, Punie, Kevin, additional, Oliveira, Júlio, additional, Michielin, Olivier, additional, Dafni, Urania, additional, Peters, Solange, additional, Pentheroudakis, George, additional, and Romano, Emanuela, additional

Published
2023
Full Text
View/download PDF

42. Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data

Author

Izci, Hava, primary, Macq, Gilles, additional, Tambuyzer, Tim, additional, De Schutter, Harlinde, additional, Wildiers, Hans, additional, Duhoux, Francois P, additional, de Azambuja, Evandro, additional, Taylor, Donatienne, additional, Staelens, Gracienne, additional, Orye, Guy, additional, Hlavata, Zuzana, additional, Hellemans, Helga, additional, De Rop, Carine, additional, Neven, Patrick, additional, and Verdoodt, Freija, additional

Published
2023
Full Text
View/download PDF

43. Abstract P4-01-29: Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2- metastatic breast cancer

Author

Lambrechts, Yentl, primary, Hatse, Sigrid, additional, Kenis, Cindy, additional, Decoster, Lore, additional, de Azambuja, Evandro, additional, Jerusalem, Guy, additional, Neven, Patrick, additional, Lago, Lissandra Dal, additional, Denys, Hannelore, additional, Vuylsteke, Peter, additional, Cornelis, Frank, additional, Punie, Kevin, additional, Floris, Giuseppe, additional, Desmedt, Christine, additional, Laenen, Annouschka, additional, Pondé, Noam, additional, and Wildiers, Hans, additional

Published
2023
Full Text
View/download PDF

45. Abstract P3-05-40: Association of body mass index with clinicopathological features and survival in patients with primary ER+/HER2- invasive lobular breast cancer

Author

Van Baelen, Karen, primary, Nguyen, Ha-Linh, additional, Richard, François, additional, Hamy, Anne-Sophie, additional, Toussaint, Aullène, additional, Reyal, Fabien, additional, Salomon, Anne, additional, Dirix, Luc, additional, Vermeulen, Peter, additional, Wuyts, Hilde, additional, Karsten, Maria, additional, Dordevic, Adam D., additional, Marta, Guilherme Nader, additional, de Azambuja, Evandro, additional, Sotiriou, Christos, additional, Larsimont, Denis, additional, Amato, Ottavia, additional, Maetens, Marion, additional, De Schepper, Maxim, additional, Geukens, Tatjana, additional, Han, Sileny, additional, Baert, Thaïs, additional, Punie, Kevin, additional, Wildiers, Hans, additional, Remmerie, Chantal, additional, Smeets, Ann, additional, Nevelsteen, Ines, additional, Floris, Giuseppe, additional, Biganzoli, Elia, additional, Neven, Patrick, additional, and Desmedt, Christine, additional

Published
2023
Full Text
View/download PDF

46. Abstract P2-01-04: Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

Author

Debien, Veronique, primary, Agostinetto, Elisa, additional, Sirico, Marianna, additional, Jacobs, Flavia, additional, Molinelli, Chiara, additional, Moreau, Michel, additional, Paesmans, Marianne, additional, De Giorgi, Ugo, additional, Santoro, Armando, additional, Taylor, Donatienne, additional, Duhoux, François P., additional, Botticelli, Andrea, additional, Barchiesi, Giacomo, additional, Lambertini, Matteo, additional, de Azambuja, Evandro, additional, and Piccart, Martine, additional

Published
2023
Full Text
View/download PDF

47. Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data

Author

Izci,Hava, Macq,Gilles, Tambuyzer,Tim, De Schutter,Harlinde, Wildiers,Hans, Duhoux,Francois P, de Azambuja,Evandro, Taylor,Donatienne, Staelens,Gracienne, Orye,Guy, Hlavata,Zuzana, Hellemans,Helga, De Rop,Carine, Neven,Patrick, Verdoodt,Freija, Izci,Hava, Macq,Gilles, Tambuyzer,Tim, De Schutter,Harlinde, Wildiers,Hans, Duhoux,Francois P, de Azambuja,Evandro, Taylor,Donatienne, Staelens,Gracienne, Orye,Guy, Hlavata,Zuzana, Hellemans,Helga, De Rop,Carine, Neven,Patrick, and Verdoodt,Freija

Abstract

Hava Izci,1 Gilles Macq,2 Tim Tambuyzer,2 Harlinde De Schutter,2 Hans Wildiers,1,3 Francois P Duhoux,4 Evandro de Azambuja,5 Donatienne Taylor,6 Gracienne Staelens,7 Guy Orye,8 Zuzana Hlavata,9 Helga Hellemans,10 Carine De Rop,11 Patrick Neven,1,3 Freija Verdoodt2 1KU Leuven - University of Leuven, Department of Oncology, Leuven, B-3000, Belgium; 2Belgian Cancer Registry, Research Department, Brussels, Belgium; 3University Hospitals Leuven, Multidisciplinary Breast Center, Leuven, B-3000, Belgium; 4Department of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Brussels, Belgium; 5Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B), Brussels, Belgium; 6CHU UCL Namur, Site Sainte-Elisabeth, Namur, Belgium; 7Multidisciplinary Breast Center, General Hospital Groeninge, Kortrijk, Belgium; 8Department of Obstetrics and Gynecology, Jessa Hospital, Hasselt, Belgium; 9Department of Medical Oncology, CHR Mons-Hainaut, Mons, Hainaut, Belgium; 10Department of Obstetrics and Gynaecology, AZ Delta, Roeselaere, Belgium; 11Department of Obstetrics and Gynaecology, Imelda Hospital, Bonheiden, BelgiumCorrespondence: Hava Izci, KU Leuven, Department of oncology, Herestraat 49 Box 7003-06, Leuven, 3000, Belgium, Email hava.izci@kuleuven.bePurpose: High-quality population-based cancer recurrence data are scarcely available, mainly due to complexity and cost of registration. For the first time in Belgium, we developed a tool to estimate distant recurrence after a breast cancer diagnosis at the population level, based on real-world cancer registration and administrative data.Methods: Data on distant cancer recurrence (including progression) from patients diagnosed with breast cancer between 2009– 2014 were collected from medical files at 9 Belgian centers to train, test and externally validate an algorithm (i.e., gold standard). Distant recurrence was defined as the occurrence of distant metastases between 120 days and within 10 yea

Published
2023

48. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis.

Author

Arecco, Luca, Blondeaux, Eva, Bruzzone, Marco, Latocca, Maria Maddalena, Mariamidze, Elene, Begijanashvili, Salome, Sokolovic, Emir, Gentile, Giulia, Scavone, Graziana, Ottonello, Silvia, Boutros, Andrea, Vaz-Luis, Ines, Saura, Cristina, Anderson, R A, Demeestere, Isabelle, Azim, H A, de Azambuja, Evandro, Peccatori, Fedro Alessandro, Del Mastro, L, Partridge, Ann H, Lambertini, Matteo Md Phd M., Arecco, Luca, Blondeaux, Eva, Bruzzone, Marco, Latocca, Maria Maddalena, Mariamidze, Elene, Begijanashvili, Salome, Sokolovic, Emir, Gentile, Giulia, Scavone, Graziana, Ottonello, Silvia, Boutros, Andrea, Vaz-Luis, Ines, Saura, Cristina, Anderson, R A, Demeestere, Isabelle, Azim, H A, de Azambuja, Evandro, Peccatori, Fedro Alessandro, Del Mastro, L, Partridge, Ann H, and Lambertini, Matteo Md Phd M.

Abstract

Despite increasing evidence on the safety of pregnancy after anticancer treatments in breast cancer survivors, many physicians and patients remain concerned about a potential risk of pregnancy specifically in the case of hormone receptor-positive breast cancer., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2023

49. Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer

Author

Lambertini, Matteo, Ceppi, Marcello, Anderson, Richard A, Cameron, David A, Bruzzone, Marco, Franzoi, Maria Alice, Massarotti, Claudia, El-Abed, Sarra, Wang, Yingbo, Lecocq, Christophe, Nuciforo, Paolo, Rolyance, Rebecca, Pusztai, Lajos, Sohn, Joohyuk, Latocca, Maria Maddalena, Arecco, Luca, Pistilli, Barbara, Ruddy, Kathryn J, Ballestrero, Alberto, Del Mastro, Lucia, Peccatori, Fedro Alessandro, Partridge, Ann H, Saura, Cristina, Untch, Michael, Piccart, Martine, Di Cosimo, Serena, de Azambuja, Evandro, Demeestere, Isabelle, Lambertini, Matteo, Ceppi, Marcello, Anderson, Richard A, Cameron, David A, Bruzzone, Marco, Franzoi, Maria Alice, Massarotti, Claudia, El-Abed, Sarra, Wang, Yingbo, Lecocq, Christophe, Nuciforo, Paolo, Rolyance, Rebecca, Pusztai, Lajos, Sohn, Joohyuk, Latocca, Maria Maddalena, Arecco, Luca, Pistilli, Barbara, Ruddy, Kathryn J, Ballestrero, Alberto, Del Mastro, Lucia, Peccatori, Fedro Alessandro, Partridge, Ann H, Saura, Cristina, Untch, Michael, Piccart, Martine, Di Cosimo, Serena, de Azambuja, Evandro, and Demeestere, Isabelle

Abstract

info:eu-repo/semantics/published

Published
2023

50. Safety of pregnancy after early breast cancer in young women with hormone receptor-positive disease :a systematic review and meta-analysis

Author

ESHRE annual meeting (39 th: 25th-28th June 2023: Copenhagen, Denmark), Arecco, Luca, Blondeaux, Eva, Bruzzone, Marco, Latocca, M M, Mariamidze, Elene, Begijanashvili, Salome, Sokolovic, Emir, Scavone, Graziana, Ottonello, Silvia, Boutros, Andrea, Vaz-Luis, Ines, Saura, Cristina, Anderson, Richard A, Demeestere, Isabelle, Azim, Hatem A, de Azambuja, Evandro, Del Mastro, Lucia, Peccatori, Fedro Alessandro, Partridge, Ann H, Lambertini, Matteo, ESHRE annual meeting (39 th: 25th-28th June 2023: Copenhagen, Denmark), Arecco, Luca, Blondeaux, Eva, Bruzzone, Marco, Latocca, M M, Mariamidze, Elene, Begijanashvili, Salome, Sokolovic, Emir, Scavone, Graziana, Ottonello, Silvia, Boutros, Andrea, Vaz-Luis, Ines, Saura, Cristina, Anderson, Richard A, Demeestere, Isabelle, Azim, Hatem A, de Azambuja, Evandro, Del Mastro, Lucia, Peccatori, Fedro Alessandro, Partridge, Ann H, and Lambertini, Matteo

Abstract

info:eu-repo/semantics/nonPublished

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results